Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.91

€1.91

1.600%
0.03
1.600%
-

-

 
17.06.21 / Frankfurt WKN: A2JLZ3 / Name: Immunovaccine / Stock / Biotechnology & Medical Research / Small Cap /

Immunovaccine Inc Stock

There is an upward development for Immunovaccine Inc compared to yesterday, with an increase of €0.030 (1.600%).

Pros and Cons of Immunovaccine Inc in the next few years

Pros
?
Worthwhile Investment for the next years
?
Shareholder structure
?
Conscious of the environment
Cons
?
Brand
?
Market Position
?
Growth compared to competition
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Immunovaccine Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Immunovaccine Inc 1.600% -2.051% 2.688% -24.206% -23.600% -55.122% 40.772%
Oncolytics Biotech -0.870% -8.800% 5.556% 38.182% 15.152% -56.154% -23.077%
Nymox Pharmaceutical Corp. -4.350% -8.392% -9.028% -64.595% -37.019% -55.743% -38.469%
Aurinia Pharmaceuticals Inc. -2.830% -2.351% 0.693% -28.345% -10.431% 112.422% -

Other discussions about Immunovaccine Inc Stock

New thread Forum

News

IMV Announces Appointment of Jeremy R. Graff, Ph.D. as Chief Scientific Officer And Addition of Clinical Advisor: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Announces Appointment of Jeremy R. Graff, Ph.D. as Chief Scientific Officer And Addition of Clinical Advisor


IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced the appointment of

Independent Proxy Advisory Firms Recommend IMV Shareholders Vote for All Director Nominees at the Upcoming Annual General and Special Meeting: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
Independent Proxy Advisory Firms Recommend IMV Shareholders Vote for All Director Nominees at the Upcoming Annual General and Special Meeting


IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious

IMV Inc. to Present at Two Upcoming Investor Conferences: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Inc. to Present at Two Upcoming Investor Conferences


IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV’s executive management team will be participating in two upcoming investor conferences.



Sachs